| Protocols | Back To Search Instructions | |
|---|---|---|
| 2 protocol(s) meet the specified criteria | ||
| Disease Site: Esophagus | ||
| Protocol No. | Title | Status |
| 19108GCCC | 19108GCCC: A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Open |
| 22121GCCC | 22121GCCC: A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Open |